Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa

Journal of Infection and Chemotherapy

Volumn 17, Issue 5, 2011, Pages 726-730

  Deguchi, Takashi ^a   Seike, Kensaku ^a   Yasuda, Mitsuru ^a   Matsumoto, Tetsuro ^b  

^a GIFU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Complicated urinary tract infection; Levofloxacin; Monte Carlo simulation; Pharmacokinetics pharmacodynamics (PK PD)

Indexed keywords

LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; CYSTITIS; DOSAGE SCHEDULE COMPARISON; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HUMAN; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PROBABILITY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; URINARY TRACT INFECTION;

EID: 84855432761     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0231-4     Document Type: Article

References (11)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
2. Rybak MJ. Pharmacodynamics: Relation to antimicrobial resistance. Am J Infect Control. 2006;34(Suppl 1):S38-45. (Pubitemid 43928178)
3. Kohn S, Watanabe A, Aoki N, Niki Y, Kadota J, Fujita J, et al. Clinical response of levofloxacin 500 mg qd to respiratory tract infection. Jpn J Chemother. 2009;57(S-2):20-33.
4. Matsumoto T, Yasuda M, Arakawa S, Monden K, Muratani T, Hori S. Clinical response of levofloxacin 500 mg qd to complicated urinary tract infection. Efficacy of 7-and 14-day administration. Jpn J Chemother. 2009;57(S-2):34-46.
5. Tanigawara Y, Shimizu T, Totsuka K. Population pharmacokinetics and pharmacodynamics of 500 mg oral dose levofloxacin in respiratory tract infection patients. Jpn J Chemother. 2009; 57(S-2):47-54.
6. Deguchi T, Nakane K, Yasuda M, Shimizu T, Monden K, Arakawa S, et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: A pharmacokinetic/ pharmacodynamic Analysis. Int J Antimicrob Agents. 2010; 35:573-7.
7. Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami K, et al. Sensitivity of major causative urinary tract infection bacteria to various antimicrobial agents. Jpn J Chemother. 2010;58:466-82.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Clinical and Laboratory Standards Institute Document M100-S17. Wayne: CLSI; 2007.
9. Mikamo H, Tanaka K, Watanabe K. Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae and Haemophilus influenzae with the use of Monte Carlo simulation. Jpn J Antibiot. 2006;59:468-73. (Pubitemid 46212604)
10. Kanda H, Chiba M, Inoue K, Hoshino K, Tanaka M, Otani T, et al. Evaluation of lovofloxacin dosage regimens to prevent the appearance of resistant mutants in Streptococcus pneumoniae and Escherichia coli using an in vitro simulation model. Jpn J Chemother. 2009;57:1-14.
11. Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: Effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991;164:499-506.